目的研究IL-32γ可否诱导肝星状细胞LX-2表达Ⅰ型胶原(CollagenⅠ)。方法不同浓度的IL-32γ与LX-2共培养,分别收集培养上清液、提取细胞总RNA,real-time PCR检测CollagenⅠmRNA表达水平,ELISA法检测CollagenⅠ蛋白质表达水平。用不同浓...目的研究IL-32γ可否诱导肝星状细胞LX-2表达Ⅰ型胶原(CollagenⅠ)。方法不同浓度的IL-32γ与LX-2共培养,分别收集培养上清液、提取细胞总RNA,real-time PCR检测CollagenⅠmRNA表达水平,ELISA法检测CollagenⅠ蛋白质表达水平。用不同浓度的人重组磷酸化p38α蛋白(recombinant human active p38α蛋白)与LX-2细胞共培养,48 h后收集细胞培养上清液,ELISA法检测CollagenⅠ蛋白质表达水平。再用不同浓度的p38MAPK抑制剂SB203580加入LX-2细胞与IL-32γ共培养的培养液中,分别收集培养上清液,采用ELISA检测CollagenⅠ蛋白质表达水平,同时提取细胞总RNA采用real-time PCR检测CollagenⅠmRNA表达水平。结果 IL-32γ诱导人LX-2细胞表达CollagenⅠ,且其表达水平随IL-32γ浓度的增加而增强;人重组磷酸化p38α蛋白可诱导LX-2细胞表达CollagenⅠ增高,阻断p38MAPK可降低IL-32γ诱导的CollagenⅠ表达。结论 IL-32γ通过活化p38MAPK通路诱导LX-2细胞表达CollagenⅠ,IL-32γ可能通过诱导肝星状细胞表达CollagenⅠ而参与肝纤维化的形成。展开更多
[目的]建立人肝星状细胞(LX-2)与人肾小管上皮细胞(HK-2)共培养体系的理论模型,研究LX-2对HK-2转分化的影响。[方法]以Transwell小室建立体外LX-2细胞和HK-2细胞间接共培养体系。应用细胞免疫组织化学法检测HK-2细胞平滑肌肌动蛋白(α-S...[目的]建立人肝星状细胞(LX-2)与人肾小管上皮细胞(HK-2)共培养体系的理论模型,研究LX-2对HK-2转分化的影响。[方法]以Transwell小室建立体外LX-2细胞和HK-2细胞间接共培养体系。应用细胞免疫组织化学法检测HK-2细胞平滑肌肌动蛋白(α-SMA)表达;用酶联免疫吸附法(ELISA法)检测各组细胞培养液中转化生长因子-β1(TGF-β1)的含量;逆转录-聚合酶链反应法(RT-PCR法)检测HK-2细胞TβRⅠm RNA、TβRⅡm RNA、Smad2 m RNA、Smad3 m RNA、Smad7 m RNA的表达。[结果]除了空白组,形态学上其他两组均可看到HK-2细胞胞浆染棕黄色,不同数量细胞由立方铺路石样转变为梭形长条状,细胞肥大;HK-2细胞高表达α-SMA(P<0.01);HK-2细胞上清液中TGF-β1含量明显高于空白组(P<0.01);HK-2细胞TβRⅠ、Smad2、Smad3基因表达明显上调,而TβRⅡ、Smad7基因表达明显下调。[结论]Transwell共培养法可诱导HK-2细胞转分化,其机制可能与TGF-β1/Smad信号通路有关。展开更多
目的研究LX-2细胞中PPARγ和i NOS的动态变化及关系,探讨PPARγ抗肝纤维化机制。方法体外培养LX-2细胞,实验分4组:PPARγ激动剂组;PPARγ拮抗剂组;联合干预组;空白对照组。分别加入干预药物培养48小时,采用MTT法检测细胞增殖率;RT-PCR...目的研究LX-2细胞中PPARγ和i NOS的动态变化及关系,探讨PPARγ抗肝纤维化机制。方法体外培养LX-2细胞,实验分4组:PPARγ激动剂组;PPARγ拮抗剂组;联合干预组;空白对照组。分别加入干预药物培养48小时,采用MTT法检测细胞增殖率;RT-PCR法测各组PPARγ、i NOS m RNA表达;硝酸还原酶法测NO含量;ELISA法测上清液的Ⅰ型胶原、αSMA的含量。结果 1MTT结果示:激动剂组的LX-2增殖抑制作用明显,与联合干预组、抑制剂组及空白对照组相比,具有显著性差异(aP=0.000,bP=0.007,cP=0.003)。2RT-PCR结果示:激动剂组PPARγm RNA的表达较其他3组明显升高(dP=0.005,eP=0.004,fP=0.008);激动剂组i NOS m RNA的表达较其他3组明显降低(aP=0.001,bP=0.003,cP=0.000);且PPARγ与i NOS m RNA表达呈负相关(相关指数为r=-0.8870,P=0.0080)。3硝酸还原酶结果示:激动剂组NO含量(44.89±13.01)μmol/L明显低于其他3组,具有显著性差异(aP=0.001,bP=0.000,cP=0.003)。4ELISA检测结果示:激动剂组Ⅰ型胶原含量(31.807±1.680)ng/ml、α-SMA的表达量(23.351±2.801)ng/ml与其他3组相比,具有显著性差异(aP=0.007,bP=0.009,cP=0.005,dP=0.004,eP=0.003,fP=0.003)。结论 PPARγ激动剂可以上调PPARγ的表达,抑制LX-2增殖,下调i NOS m RNA表达,减少NO产生,降低Ⅰ型胶原及α-SMA分泌,发挥抗纤维化作用;并发现PPARγ与i NOS m RNA的表达具有负相关关系。展开更多
AIM: To investigate the effect of herbal compound 861 (Cpd861) on the transforming growth factor-β1 (TGFβ1)/ activin receptor-like kinase 1 (ALK1, type Ⅰ receptor) signaling-pathway-related gene expression in the L...AIM: To investigate the effect of herbal compound 861 (Cpd861) on the transforming growth factor-β1 (TGFβ1)/ activin receptor-like kinase 1 (ALK1, type Ⅰ receptor) signaling-pathway-related gene expression in the LX-2 cell line, and the inhibitory mechanism of Cpd861 on the activation of LX-2 cells. METHODS: LX-2 cells were treated with TGFβ1 (5 ng/mL) Cpd861 (0.1 mg/mL), TGFβ1 (5 ng/mL) plus Cpd861 (5 ng/mL) for 24 h to investigate the effect of Cpd861 on the TGFβ1/ALK1 pathway. Real-time PCR was performed to examine the expression of α-SMA (α-smooth muscle actin), ALK1, Id1 (inhibitor of differentiation 1). Western blotting was carried out to measure the levels of α-SMA and phosphorylated Smad1, and immunocytochemical analysis for the expression of α-SMA. RESULTS: In LX-2 cells, TGFβ1/ALK1-pathway-related gene expression could be stimulated by TGFβ1, which led to excessive activation of the cells. Cpd861 decreased the activation of LX-2 cells by reducing the expression of α-SMA mRNA and protein expression. This effect was related to inhibition of the above TGFβ1/ALK1-pathway- related expression of genes such as Id1 and ALK1, and phosphorylation of Smad1 in LX-2 cells, even with TGFβ1 co-treatment for 24 h. CONCLUSION: Cpd861 can restrain the activation of LX-2 cells by inhibiting the TGFβ1/ALK1/Smad1 pathway.展开更多
文摘目的研究IL-32γ可否诱导肝星状细胞LX-2表达Ⅰ型胶原(CollagenⅠ)。方法不同浓度的IL-32γ与LX-2共培养,分别收集培养上清液、提取细胞总RNA,real-time PCR检测CollagenⅠmRNA表达水平,ELISA法检测CollagenⅠ蛋白质表达水平。用不同浓度的人重组磷酸化p38α蛋白(recombinant human active p38α蛋白)与LX-2细胞共培养,48 h后收集细胞培养上清液,ELISA法检测CollagenⅠ蛋白质表达水平。再用不同浓度的p38MAPK抑制剂SB203580加入LX-2细胞与IL-32γ共培养的培养液中,分别收集培养上清液,采用ELISA检测CollagenⅠ蛋白质表达水平,同时提取细胞总RNA采用real-time PCR检测CollagenⅠmRNA表达水平。结果 IL-32γ诱导人LX-2细胞表达CollagenⅠ,且其表达水平随IL-32γ浓度的增加而增强;人重组磷酸化p38α蛋白可诱导LX-2细胞表达CollagenⅠ增高,阻断p38MAPK可降低IL-32γ诱导的CollagenⅠ表达。结论 IL-32γ通过活化p38MAPK通路诱导LX-2细胞表达CollagenⅠ,IL-32γ可能通过诱导肝星状细胞表达CollagenⅠ而参与肝纤维化的形成。
文摘[目的]建立人肝星状细胞(LX-2)与人肾小管上皮细胞(HK-2)共培养体系的理论模型,研究LX-2对HK-2转分化的影响。[方法]以Transwell小室建立体外LX-2细胞和HK-2细胞间接共培养体系。应用细胞免疫组织化学法检测HK-2细胞平滑肌肌动蛋白(α-SMA)表达;用酶联免疫吸附法(ELISA法)检测各组细胞培养液中转化生长因子-β1(TGF-β1)的含量;逆转录-聚合酶链反应法(RT-PCR法)检测HK-2细胞TβRⅠm RNA、TβRⅡm RNA、Smad2 m RNA、Smad3 m RNA、Smad7 m RNA的表达。[结果]除了空白组,形态学上其他两组均可看到HK-2细胞胞浆染棕黄色,不同数量细胞由立方铺路石样转变为梭形长条状,细胞肥大;HK-2细胞高表达α-SMA(P<0.01);HK-2细胞上清液中TGF-β1含量明显高于空白组(P<0.01);HK-2细胞TβRⅠ、Smad2、Smad3基因表达明显上调,而TβRⅡ、Smad7基因表达明显下调。[结论]Transwell共培养法可诱导HK-2细胞转分化,其机制可能与TGF-β1/Smad信号通路有关。
文摘目的研究LX-2细胞中PPARγ和i NOS的动态变化及关系,探讨PPARγ抗肝纤维化机制。方法体外培养LX-2细胞,实验分4组:PPARγ激动剂组;PPARγ拮抗剂组;联合干预组;空白对照组。分别加入干预药物培养48小时,采用MTT法检测细胞增殖率;RT-PCR法测各组PPARγ、i NOS m RNA表达;硝酸还原酶法测NO含量;ELISA法测上清液的Ⅰ型胶原、αSMA的含量。结果 1MTT结果示:激动剂组的LX-2增殖抑制作用明显,与联合干预组、抑制剂组及空白对照组相比,具有显著性差异(aP=0.000,bP=0.007,cP=0.003)。2RT-PCR结果示:激动剂组PPARγm RNA的表达较其他3组明显升高(dP=0.005,eP=0.004,fP=0.008);激动剂组i NOS m RNA的表达较其他3组明显降低(aP=0.001,bP=0.003,cP=0.000);且PPARγ与i NOS m RNA表达呈负相关(相关指数为r=-0.8870,P=0.0080)。3硝酸还原酶结果示:激动剂组NO含量(44.89±13.01)μmol/L明显低于其他3组,具有显著性差异(aP=0.001,bP=0.000,cP=0.003)。4ELISA检测结果示:激动剂组Ⅰ型胶原含量(31.807±1.680)ng/ml、α-SMA的表达量(23.351±2.801)ng/ml与其他3组相比,具有显著性差异(aP=0.007,bP=0.009,cP=0.005,dP=0.004,eP=0.003,fP=0.003)。结论 PPARγ激动剂可以上调PPARγ的表达,抑制LX-2增殖,下调i NOS m RNA表达,减少NO产生,降低Ⅰ型胶原及α-SMA分泌,发挥抗纤维化作用;并发现PPARγ与i NOS m RNA的表达具有负相关关系。
文摘AIM: To investigate the effect of herbal compound 861 (Cpd861) on the transforming growth factor-β1 (TGFβ1)/ activin receptor-like kinase 1 (ALK1, type Ⅰ receptor) signaling-pathway-related gene expression in the LX-2 cell line, and the inhibitory mechanism of Cpd861 on the activation of LX-2 cells. METHODS: LX-2 cells were treated with TGFβ1 (5 ng/mL) Cpd861 (0.1 mg/mL), TGFβ1 (5 ng/mL) plus Cpd861 (5 ng/mL) for 24 h to investigate the effect of Cpd861 on the TGFβ1/ALK1 pathway. Real-time PCR was performed to examine the expression of α-SMA (α-smooth muscle actin), ALK1, Id1 (inhibitor of differentiation 1). Western blotting was carried out to measure the levels of α-SMA and phosphorylated Smad1, and immunocytochemical analysis for the expression of α-SMA. RESULTS: In LX-2 cells, TGFβ1/ALK1-pathway-related gene expression could be stimulated by TGFβ1, which led to excessive activation of the cells. Cpd861 decreased the activation of LX-2 cells by reducing the expression of α-SMA mRNA and protein expression. This effect was related to inhibition of the above TGFβ1/ALK1-pathway- related expression of genes such as Id1 and ALK1, and phosphorylation of Smad1 in LX-2 cells, even with TGFβ1 co-treatment for 24 h. CONCLUSION: Cpd861 can restrain the activation of LX-2 cells by inhibiting the TGFβ1/ALK1/Smad1 pathway.
